Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Perhexiline.

Cardiovascular drug reviews - 1 Jan 2007

Ashrafian Houman, Horowitz John D, Frenneaux Michael P

Abstract excerpt

Perhexiline, 2-(2,2-dicyclohexylethyl)piperidine, was originally developed as an anti-anginal drug in the 1970s. Despite its success, its use diminished due to the occurrence of poorly understood side effects including neurotoxicity and hepatotoxicity in a small proportion of patients. Recently,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angina Pectoris
Share to Aortic Valve Stenosis
Share to Calcium Channel Blockers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carnitine O-Palmitoyltransferase

Share to Chemical and Drug Induced Liver Injury

Share to Drug Monitoring

Share to Neurotoxicity Syndromes

Share to Vasodilator Agents

Source

Identifiers

PMID: 17445089
DOI: 10.1111/j.1527-3466.2007.00006.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17445089-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Perhexiline.PMID 17445089Read ↗

Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy.Semantic proximity Read ↗

Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.Semantic proximity Read ↗

French‐Speaking Network of Pharmacogenetics ( RNPGx ) Recommendations for Clinical Use of MavacamtenSemantic proximity Read ↗

Proton Pump Inhibitors and Cardiac Safety: Emerging Evidence Linking Cardiovascular Disease, Arrhythmias, and Mechanistic PathwaysSemantic proximity Read ↗

Exploration of clozapine-induced cardiomyopathy and its mechanismSemantic proximity Read ↗

Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathySemantic proximity Read ↗

The KHENERGY Study: Safety and Efficacy of KH176 in Mitochondrial m.3243A>G Spectrum Disorders.Semantic proximity Read ↗

Comparative profiling of carnitine palmitoyltransferase 1 isoforms reveals vincamine as a selective carnitine palmitoyltransferase 1b inhibitorSemantic proximity Read ↗

Overview of fenofibrate.Semantic proximity Read ↗

The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia.Semantic proximity Read ↗

Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.Semantic proximity Read ↗

Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.